A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01237678. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study to Assess the Safety and Efficacy of Lorvotuzumab Mertansine in Combination With Carboplatin/Etoposide in Patients With Advanced Solid Tumors Including Extensive Stage Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to test safety and efficacy of this combination treatment (IMGN901, carboplatin and etoposide) in patients with solid tumors and extensive stage small cell lung cancer.
Study identification
- NCT ID
- NCT01237678
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 181 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2010 (Type not available)
- Primary completion
- May 2015 (Actual)
- Completion
- May 2015 (Actual)
- Last update posted
- Jan 18, 2018
2010 – 2015
United States locations
- U.S. sites
- 32
- U.S. states
- 17
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Cancer Center @ UMC North | Tucson | Arizona | 85719 | — |
| UCLA Oncology Center | Los Angeles | California | 90095 | — |
| St. Joseph's Hospital | Orange | California | 92868 | — |
| UCLA Hematology | Pasadena | California | 91105 | — |
| UCLA Oncology Clinic | Santa Monica | California | 90404 | — |
| UCLA Santa Clarita Valley Cancer Center | Valencia | California | 91355 | — |
| UCLA Oncology Center | Westlake Village | California | 91361 | — |
| Yale Medical Center | New Haven | Connecticut | 06510 | — |
| Sibley Memorial Hospital | Washington D.C. | District of Columbia | 20016 | — |
| Holy Cross Hospital Bienes Comprehensive Cancer Center | Fort Lauderdale | Florida | 33308 | — |
| University of Florida | Gainesville | Florida | 32608 | — |
| Anne Arundel Medical Center | Annapolis | Maryland | 21401 | — |
| Greater Baltimore Medical Center | Baltimore | Maryland | 21204 | — |
| Bayview Medical Center | Baltimore | Maryland | 21224 | — |
| Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114-2696 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Johnson Therurer Cancer Center at Hackensack | Hackensack | New Jersey | 07601 | — |
| University Hospitals of Cleveland | Cleveland | Ohio | 44106 | — |
| Oklahoma University | Oklahoma City | Oklahoma | 73104-5417 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| UPMC Cancer Centers East, Oxford Drive | Monroeville | Pennsylvania | 15146 | — |
| UPMC Cancer Center St. Margaret | Pittsburgh | Pennsylvania | 15215 | — |
| Univeristy of Pittsburg Medical Center | Pittsburgh | Pennsylvania | 15232 | — |
| UPMC Cancer Center at UPMC Passavant (HOA) | Pittsburgh | Pennsylvania | 15237 | — |
| South Carolina Oncology Associates | Columbia | South Carolina | 29210 | — |
| University of Tennessee Medical Center Cancer Institute | Knoxville | Tennessee | 37920 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| UTHSC at San Antonio | San Antonio | Texas | 78229 | — |
| Northwest Medical Specialties | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01237678, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 18, 2018 · Synced Nov 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.